Hualan Biological Engineering Inc.
Shenzhen Stock ExchangeTotal Valuation
Hualan Biological Engineering Inc. carries a market capitalization of 23.17B, placing it among publicly traded companies globally. Its enterprise value stands at 27.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 23.17B |
| Enterprise Value | 27.93B |
Share Statistics
Hualan Biological Engineering Inc. currently has 1.83B shares outstanding.
| Shares Outstanding | 1.83B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Hualan Biological Engineering Inc. trades at a trailing price-to-earnings ratio of 24.59. The price-to-sales ratio is 6.32, and the price-to-book ratio stands at 2.95.
| PE Ratio | 24.59 |
| PS Ratio | 6.32 |
| PB Ratio | 2.95 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | 267.29 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Hualan Biological Engineering Inc. trades at an EV/EBITDA multiple of 20.43 and an EV/FCF ratio of 240.54. The EV/Sales ratio of 6.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.43 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.17 |
| EV / EBITDA | 20.43 |
| EV / EBIT | 20.43 |
| EV / FCF | 240.54 |
Financial Position
Hualan Biological Engineering Inc. maintains a current ratio of 6.37, meaning it holds 6.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.07, indicating elevated leverage, while an interest coverage ratio of 133.62 demonstrates strong ability to service its debt obligations.
| Current Ratio | 6.37 |
| Quick Ratio | 2.00 |
| Debt / Equity | 2.07 |
| Debt / EBITDA | 0.21 |
| Interest Coverage | 133.62 |
Financial Efficiency
Hualan Biological Engineering Inc. posts a return on equity of 12.43 and a return on invested capital of 8.34.
| Return on Equity (ROE) | 12.43 |
| Return on Assets (ROA) | 7.46 |
| Return on Invested Capital (ROIC) | 8.34 |
| Return on Capital Employed (ROCE) | 9.23 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.82 |
Taxes
Over the trailing twelve months, Hualan Biological Engineering Inc. has paid 186.75M in income taxes, reflecting an effective tax rate of 13.19.
| Income Tax | 186.75M |
| Effective Tax Rate | 13.19 |
Stock Price Statistics
Hualan Biological Engineering Inc.'s stock has declined approximately -19.78508% over the past 52 weeks. The 50-day moving average sits at 13.57, while the 200-day moving average is 15.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.78508% |
| 50-Day Moving Average | 13.57 |
| 200-Day Moving Average | 15.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Hualan Biological Engineering Inc. generated 4.52B in revenue and converted that into 1.16B in net income, yielding earnings per share of 0.67. EBITDA reached 1.37B, while operating income came in at 1.37B.
| Revenue | 4.52B |
| Gross Profit | 2.80B |
| Operating Income | 1.37B |
| Pretax Income | 1.42B |
| Net Income | 1.16B |
| EBITDA | 1.37B |
| EBIT | 1.37B |
| Earnings Per Share (EPS) | 0.67 |
Balance Sheet
Hualan Biological Engineering Inc. holds 2.93B in cash and equivalents against 288.59M in total debt, resulting in a net debt position of -880.35M. Total book value stands at 9.71B, with working capital of 7.87B providing operational flexibility.
| Cash & Cash Equivalents | 2.93B |
| Total Debt | 288.59M |
| Net Debt | -880.35M |
| Equity (Book Value) | 9.71B |
| Book Value Per Share | 5.32 |
| Working Capital | 7.87B |
Cash Flow
After subtracting -107.23M in capital expenditures, free cash flow totaled -107.23M - equivalent to -0.06 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -107.23M |
| Free Cash Flow | -107.23M |
| FCF Per Share | -0.06 |
Margins
Hualan Biological Engineering Inc. operates with a gross margin of 61.85, reflecting its pricing power and cost economics. The operating margin of 30.22 and net profit margin of 25.71 provide insight into operational efficiency.
| Gross Margin | 61.85 |
| Operating Margin | 30.22 |
| Pretax Margin | 31.30 |
| Profit Margin | 25.71 |
| EBITDA Margin | 30.22 |
Dividends & Yields
The company's payout ratio of 25.67 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.18 |
| Dividend Yield | N/A |
| Payout Ratio | 25.67 |
| Shareholder Yield | 4.43 |
| FCF Yield | 0.37 |
Stock Splits
Hualan Biological Engineering Inc.'s most recent stock split took place on April 27, 2020 with a 10:13 split ratio.
| Last Split Date | 4/27/2020 |
| Split Ratio | 10:13 |
Scores
Hualan Biological Engineering Inc. posts an Altman Z-Score of 12.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 12.91 |